港股異動 | 康希諾生物-B漲6% 成港交所第五家去“B”生科股 獲增持
格隆匯5月27日丨康希諾生物-B(6185.HK)漲6.16%,報76.65港元;A股康希諾(688185.SH)漲11.7%,168.38元,總市值417億元。康希諾生物-B日前公佈,自5月31日起,公司的中英文股份簡稱將不再加上標記“B”。康希諾生物乃繼百濟神州、信達生物、君實生物、復宏漢霖之後,第五家去“B”生物科技股。另外,港交所股權披露資料顯示,5月23日,康希諾生物獲美國資本集團在場內以每股平均價70.657港元增持117.3萬股H股,涉資約8287.83萬港元。增持後,美國資本集團的最新持好倉數目為3166.33萬股,持好倉比例由22.98%升至23.87%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.